You are on page 1of 1

55496 Federal Register / Vol. 71, No.

184 / Friday, September 22, 2006 / Notices

requests, comments, and return address This technology describes therapeutic agents, which prevent or
to: immunogenic and therapeutic treat HEV infection, are commercially
Comment Due Date: Your comments compositions related to HIV p28TEV provided.
regarding this information collection are protein, first protein expressed during An isolated strain of swine HEV is
best assured of having their full effect if HIV infection in the case of the pHXB2 currently available for licensing and
received within 30 days of the date of isolate. p28TEV functions in the commercial development. The
this publication. regulation of HIV transcription and may nucleotide and amino acid sequences of
Dated: September 15, 2006.
be important for the expression of latent the available virus are significantly
virus. A number of p28TEV associated homologous to human HEV and
Robert G. McSwain,
compositions are available for licensing antibodies induced by the agent were
Deputy Director, Indian Health Service. and commercial development including:
[FR Doc. 06–8021 Filed 9–21–06; 8:45 am] shown to cross react with a human HEV
(1) The p28TEV polypeptide from one or antigen. The present technology
BILLING CODE 4165–16–M more HIV clades, (2) nucleic acids provides a mechanism for augmenting
encoding these p28TEV polypeptides, (3) the immune response against HEV in
a polypeptide with significant sequence infected individuals and is thus useful
DEPARTMENT OF HEALTH AND homology to p28TEV, and (4)
HUMAN SERVICES for the development of novel vaccines
immunogenic fragments of these and therapeutics for prevention and
National Institutes of Health polypeptides. Additional compositions treatment of HEV infection in humans.
include antibodies and antagonists that In addition, the available viral strain
Government-Owned Inventions; act to inhibit p28TEV activity. Adjuvants,may be used to develop diagnostic tools
Availability for Licensing immunomodulators and compounds for efficient detection of HEV
used in combination with p28TEV for the contamination of food and water in
AGENCY: National Institutes of Health, treatment of HIV infection are also developing countries, especially in
Public Health Service, HHS. included in the available technology. regions of Africa, Asia and Mexico,
ACTION: Notice. Applications: (1) Novel therapeutics where HEV is endemic.
for treatment of HIV infection; (2) Novel
SUMMARY: The inventions listed below HIV vaccine component. Applications: (1) Development of
are owned by an agency of the U.S. Development Status: Preclinical data diagnostic tools for identification and
Government and are available for are available at this time. detection of HEV infection; (2) HEV
licensing in the U.S. in accordance with Inventors: Genoveffa Franchini et al. vaccination in developing countries,
35 U.S.C. 207 to achieve expeditious (NCI) where individuals are at higher risk for
commercialization of results of Patent Status: U.S. Patent Application infection; (3) Research and development
federally-funded research and No. 11/364,873 filed 27 Feb 2006 (HHS of anti-HEV therapeutics agents.
development. Foreign patent Reference No. E–072–2004/3–US–01) Development Status: Preclinical data
applications are filed on selected Licensing Status: Available for are available at this time.
inventions to extend market coverage exclusive or non-exclusive licensing.
Licensing Contact: Susan Ano, PhD; Inventors: Xiang-jin Meng, Robert H.
for companies and may also be available Purcell, Suzanne U. Emerson (NIAID)
for licensing. Collaborative Research Opportunities: Patent Status: U.S. Patent No.
ADDRESSES: Licensing information and The National Cancer Institute Vaccine 6,432,408 issued 13 Aug 2002 (HHS
copies of the U.S. patent applications Branch is seeking statements of Reference No. E–203–1997/0–US–04)
listed below may be obtained by writing capability or interest from parties and European Patent Application No.
to the indicated licensing contact at the interested in collaborative research to 98934568 filed 17 Jul 1998 (HHS
Office of Technology Transfer, National further develop, evaluate, or Reference No. E–203–1997/0–EP–03)
Institutes of Health, 6011 Executive commercialize Methods of Targeting the
Boulevard, Suite 325, Rockville, Licensing Status: Available for non-
Establishment of the HIV Viral
Maryland 20852–3804; telephone: 301/ exclusive or exclusive licensing.
Reservoir. Please contact Betty Tong,
496–7057; fax: 301/402–0220. A signed PhD at 301–594–4263 or Licensing Contact: Chekesha
Confidential Disclosure Agreement will for more Clingman, PhD; 301/435–5018;
be required to receive copies of the information.
patent applications. Collaborative Research Opportunity:
Swine Hepatitis E Virus Available for
An HIV Protein for Use as a Novel Use in Diagnosis, Prevention and The NIAID Laboratory of Infectious
Therapeutic or Vaccine Component Treatment of Hepatitis E Diseases, Hepatitis Viruses Section, is
seeking statements of capability or
Description of Technology: Latent HIV Description of Technology: Hepatitis E interest from parties interested in
presents a challenge for complete virus (HEV) is the cause of Hepatitis E, collaborative research to further
removal of the virus in infected a liver disease that occurs primarily in develop, evaluate, or commercialize
individuals and is becoming an developing countries due to fecal swine HEV or its products. Please
increasingly important consideration in contaminated drinking water. Outbreaks contact Robert H. Purcell at
the identification of potential HIV of HEV infection have caused epidemics for more
therapeutics or treatment regimens. in Africa, Central and Southeast Asia information.
These transcriptionally inactive HIV and Mexico and cases of the disease
reservoirs lay dormant in a portion of have also been reported sporadically in Dated: September 18, 2006.
infected cells and are capable of evading more developed countries. Hepatitis E is Steven M. Ferguson,
sroberts on PROD1PC70 with NOTICES

both host defenses and existing most often overcome by a host’s natural Director, Division of Technology Development
antiretroviral therapy. The present defenses; however the disease is more and Transfer, Office of Technology Transfer,
technology offers a potential solution for severe in pregnant women, who exhibit National Institutes of Health.
complete eradication of HIV in infected a 20% mortality rate due to HEV [FR Doc. 06–8080 Filed 9–21–06; 8:45 am]
individuals. infection. Presently, no vaccines or BILLING CODE 4140–01–P

VerDate Aug<31>2005 20:37 Sep 21, 2006 Jkt 208001 PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 E:\FR\FM\22SEN1.SGM 22SEN1